Aureka Biotechnologies
AI-powered digital biology for protein therapeutics and antibody discovery
Biotechnology
📍 Laguna Hills, CA
Founded 2023
Current Valuation
Private
PRIVATE
Aureka Biotechnologies develops AI-powered digital-biology systems for discovering protein therapeutics and antibody treatments. The Laguna Hills company combines high-throughput functional screening with AI-based therapeutic design. Its $100M Series B announced on August 11, 2026 was led by Granite Asia, with HighLight Capital and Matrix Partners China among the disclosed participants.
Company Profile
Growth
$100M Series B to expand AI-native therapeutic discovery
Last Round
Series B — $100M (Aug 2026) · Lead: Granite Asia
Fundraising Status
Series B · $100M · this month
private1 disclosed rounds
Funding History
| Round | Amount | Date | Lead Investor | Post-Money |
|---|
| Series B | $100M | Aug 2026 | Granite Asia | — |
Vertical Intelligence — Biotech / Gene Therapy
Biotech / Gene Therapy registry data for Aureka Biotechnologies has not been collected yet — the weekly vertical sweep hasn't reached this company. Check back soon.
Talent Signal
Hiring data for Aureka Biotechnologies has not been collected yet — the monthly talent sweep hasn't reached this company. Check back soon.
Investors
Granite Asia · HighLight Capital · Matrix Partners China
Products
- AI-powered digital-biology platform for protein therapeutics
- High-throughput antibody discovery and design platform
BiotechnologyAIDrug DiscoveryProtein TherapeuticsSeries B
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.